Welcome to our dedicated page for nyse news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on nyse stock.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) is a pioneering biopharmaceutical company focused on developing targeted radiotherapies for treating cancer. Founded with the mission of improving survival outcomes for patients with difficult-to-treat cancers, Actinium leverages its proprietary Antibody Radiation Conjugates (ARCs) to deliver potent radiation directly to cancer cells while sparing healthy tissue.
Actinium's leading candidates include Iomab-B and Actimab-A. Iomab-B is a radioimmunotherapy intended for conditioning before bone marrow transplants in patients with active relapsed or refractory acute myeloid leukemia (r/r AML). The pivotal Phase 3 SIERRA trial has demonstrated Iomab-B's ability to significantly improve overall survival and remission rates, particularly in patients with the high-risk TP53 mutation. Advanced filings for Biologics License Application (BLA) and Marketing Authorization Application (MAA) are underway.
Actimab-A, targeting CD33, is being developed as a therapeutic for r/r AML and is currently progressing under the National Cancer Institute’s CRADA pivotal development path. This candidate, along with Iomab-B, has shown promising results in overcoming genetic mutations and providing high response rates.
In addition to its robust pipeline, Actinium is actively involved in partnerships to extend its technology platform to solid tumors. Notable collaborations include those with Astellas Pharma, AVEO Oncology, and LG Chem Life Sciences. The company holds an extensive intellectual property portfolio with over 230 patents and patent applications.
Recent developments include the initiation of a clinical trial for Iomab-ACT, a next-generation conditioning agent for cell and gene therapies such as CAR T-cell therapy. This trial, led by the University of Texas Southwestern Medical Center, aims to replace traditional chemotherapy conditioning with targeted radiotherapy to reduce toxicities and improve patient outcomes.
Actinium’s strong presence at major scientific conferences such as the American Society of Hematology (ASH), European Bone Marrow Transplant Society (EBMT), and Tandem Meetings of ASTCT and CIBMTR underscores its commitment to advancing targeted radiotherapies and highlights the potential of its innovative treatments in transforming cancer care.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in relapsed/refractory acute myeloid leukemia (r/r AML) patients aged 55 and older, achieving a durable complete remission (dCR) rate of 75% (44/59 patients) and doubling overall survival at 1 year compared to the control arm. The company plans to submit a Biologics License Application (BLA) for Iomab-B in the second half of 2023 and is launching an Early Access Program. Actimab-A also demonstrated promising 1-year survival rates in a trial subset. With a strong financial position of $108.9 million, Actinium aims to fund operations through 2025.
Actinium Pharmaceuticals (NYSE: ATNM) announced the acceptance of two abstracts for presentation at the AACR 2023 Annual Meeting, scheduled for April 14-19, 2023, in Orlando, Florida. The abstracts focus on the novel application of Actimab-A to deplete immunosuppressive myeloid-derived suppressor cells (MDSCs) and the effectiveness of HER3-targeting radiotherapy in solid tumors, showcasing potent anti-cancer activity. Actinium's Chairman, Sandesh Seth, emphasized the company's commitment to advancing targeted radiotherapies to address significant medical needs, supported by their recent CRADA with the NCI for developing Actimab-A in various clinical trials.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced its participation in Oppenheimer's 33rd Annual Healthcare Conference from March 13-17, 2023. The management team will present key updates, including the success of the pivotal Phase 3 SIERRA trial for Iomab-B, which achieved significant remissions in elderly patients with relapsed acute myeloid leukemia (AML). The Company has also signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to advance Actimab-A. The virtual presentation is scheduled for March 15, 2023, at 2:40 PM ET. More details can be found on Actinium's website.
On February 24, 2023, Hugoton Royalty Trust (HGTXU) announced the outcome of a special unitholder meeting held on February 23, 2023. Unitholders approved the appointment of Argent Trust Company as the successor trustee, contingent upon Simmons Bank's resignation. However, related amendments to the Trust's indenture did not receive enough votes for approval. The effective date for Simmons Bank's resignation depends on the fulfillment of certain conditions outlined in the trustee's notice. The press release also includes forward-looking statements that emphasize the uncertainty surrounding the transition and potential implications for the Trust's future operations.
Actinium Pharmaceuticals (NYSE: ATNM) reported positive survival data from its Actimab-A and CLAG-M combination trial for relapsed or refractory acute myeloid leukemia (AML) patients. Key findings include a 59% one-year overall survival for patients previously treated with Venetoclax, 75% measurable residual disease negativity, and a manageable safety profile. Notably, patients with a TP53 mutation showed a 52% one-year overall survival. These results were shared at the 64th Annual ASH Meeting, emphasizing the potential of Actimab-A as a treatment for high-risk AML patients previously deemed difficult to treat.
BARK, Inc. (NYSE: BARK) appointed Aarti Sharma as the new Chief People Officer, effective November 7, 2022. With 20 years in HR and people strategy, Sharma previously served as Global Head of HR at Cambium Networks, where she was key in its IPO. She aims to enhance BARK’s HR functions including talent acquisition and employee engagement. BARK, recognized as one of Newsweek’s Top 100 Most Loved Workplaces, continues to focus on employee satisfaction alongside its mission to bring joy to dogs. Sharma holds degrees in Statistics and an MBA.
FAQ
What is Actinium Pharmaceuticals' primary focus?
What is Iomab-B?
What recent achievements has Actinium Pharmaceuticals made?
Who are Actinium Pharmaceuticals' key partners?
What is Actimab-A?
What are the key results from the SIERRA trial?
What is the significance of Actinium's technology platform?
How many patents does Actinium Pharmaceuticals hold?
What is the purpose of Iomab-ACT?
Where can I find more information about Actinium Pharmaceuticals?
